PRAX (Praxis Precision Medicines) Research & Development: $284.30 Mil (TTM As of Mar. 2026)


PRAX Praxis Precision Medicines Inc PRAX
38 GF Score
Price $324.01
GF Value $30.36
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Praxis Precision Medicines Research & Development?

Praxis Precision Medicines PRAX +4.88% 38 Research & Development is $284.30 Mil as of Mar. 2026. GuruFocus rates PRAX with a GF Score™ of 38/100 and a GF Value™ of $30.36 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Praxis Precision Medicines's Research & Development for the three months ended in Mar. 2026 was $77.99 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $284.30 Mil.

Praxis Precision Medicines  (NAS:PRAX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Praxis Precision Medicines Research & Development Related Terms

Praxis Precision Medicines Research & Development Historical Data

* Premium members only.

The historical data trend for Praxis Precision Medicines's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Praxis Precision Medicines Research & Development Chart

Praxis Precision Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 120.26 155.04 86.77 152.41 267.12

Praxis Precision Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.81 63.01 65.80 77.51 77.99
PRAX
38GF Score
Praxis Precision Medicines Inc PRAX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Praxis Precision Medicines Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $284.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $284.30 Mil mean?
Praxis Precision Medicines (PRAX) has a Research & Development of $284.30 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Praxis Precision Medicines and its competitors.
Is Praxis Precision Medicines' Research & Development too high?
Praxis Precision Medicines' current Research & Development is $284.30 Mil. Overall, Praxis Precision Medicines has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Praxis Precision Medicines' Research & Development compare to KRYS and CYTK?
Praxis Precision Medicines' Research & Development of $284.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Praxis Precision Medicines and its competitors. Praxis Precision Medicines's current Research & Development is $284.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Praxis Precision Medicines stock overvalued right now?
Based on GuruFocus' analysis, Praxis Precision Medicines (PRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $30.36, compared to a current price of $324.01 — trading 967.2% above its estimated fair value. The current Research & Development is $284.30 Mil. Praxis Precision Medicines' overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Praxis Precision Medicines (PRAX), the current Research & Development is $284.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Praxis Precision Medicines (PRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Praxis Precision Medicines stock appears to be overvalued. The current stock price of $324.01 is trading 967.2% above its estimated GF Value™ of $30.36. GuruFocus considers Praxis Precision Medicines to be Significantly Overvalued.

Key valuation signals for PRAX:

  • Research & Development: $284.30 Mil
  • GF Value™: $30.36 vs. price of $324.01 (967.2% above fair value)
  • GF Score™: 38/100 with 1 warning sign

No single metric tells the full story. See the PRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Praxis Precision Medicines Business Description

Address 99 High Street, 30th Floor, Boston, MA, USA, 02110
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
38GF Score

Get the complete analysis for PRAX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$324.01
Price
$30.36
GF Value